Zevra Therapeutics (ZVRA) Cash from Investing Activities (2014 - 2026)

Zevra Therapeutics has reported Cash from Investing Activities for 13 years, with the latest figure at $79.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 655.25% year-over-year to $79.6 million; the trailing twelve-month figure through Mar 2026 stood at $87.2 million (up 430.16% YoY), and the FY2025 full-year result was $18.1 million, up 181.8% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $79.6 million, up from $227000.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $79.6 million in Q1 2026, with the low at -$44.5 million in Q3 2023.
• Historically, Cash from Investing Activities has averaged $1.3 million across 5 years, with a median of -$63000.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 40739.51% — and 2023, when it jumped 16901.59%.
• Zevra Therapeutics' Cash from Investing Activities stood at -$63000.0 in 2022, then jumped by 16901.59% to $10.6 million in 2023, then tumbled by 151.69% to -$5.5 million in 2024, then jumped by 104.15% to $227000.0 in 2025, then surged by 34974.01% to $79.6 million in 2026.
• The last three Cash from Investing Activities figures came in at $79.6 million (Q1 2026), $227000.0 (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.